Shares of Corcept Therapeutics fell more than 50% on December 31, 2025, after the Company disclosed it had received a Complete Response Letter from the FDA for relacorilant, indicating the agency could not reach a favorable risk-benefit assessment without additional evidence of effectiveness. Block & Leviton is investigating.
Contact our attorneys for a no-cost case evaluation.